WeedMD Inc. (TSXV:WMD) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that it has launched the sale of medical cannabis oil to its growing registered patient base.

“Having taken the time to understand the needs of our patient base and market demand, we developed two unique brand of cannabis oil that are now for sale to our patients and to the seniors’ institutional market,” said Bruce Dawson-Scully, CEO of WeedMD. “Our suite of products now includes dried flower as well as cannabis oils called EntourageTM and AxisTM by WeedMD. We’ve also developed a unique awareness platform that, in addition to providing ease of access to our oil products, includes our proprietary education program to foster product awareness and cannabis education – all integral components of rolling out our robust medical cannabis oil strategy.”


“We’ve developed and perfected our oil products with the concept of whole plant medicine; utilizing the full spectrum of therapeutic compounds that cannabis has to offer and allowing more of the cannabinoids, terpenes, and flavonoids to be present for a wide range of health benefits,” said Dr. Luc Duchesne, Chief Scientific Officer, WeedMD. “Taking the time to develop specific dilutions and concentrations in a dose-controlled consumption manner is significant to our patient community and medical partners.”

Having secured a license from Health Canada on December 1, 2017 to sell cannabis oils, WeedMD’s product offerings include two cannabis oil platforms called EntourageTM (for patients registered under the Access to Cannabis for Medical Purposes Regulations program, “ACMPR”) and AxisTM (for the seniors’ care market):

ENTOURAGETM cannabis oil is specially formulated for our patients under the ACMPR program.  Named after the Entourage Effect – a term used to describe medications that utilize the full spectrum of therapeutic compounds that cannabis has to offer, it is available in three offerings: High THC oil; Hybrid – equal concentrations of THC and CBD oil; and High CBD oil.

AXISTM is a unique line specially formulated to meet the needs of seniors, offering consistent concentrations that permit medical practitioners to easily convert dosages from synthetic cannabinoid medications. It is also available in high THC oil and a Hybrid variant – equal concentrations of THC and CBD oil.

The Company is committed to ensuring that its cannabis oils combined with its educational and product platforms meet the needs of all its markets. See video here. All oil products are now available for purchase by current medical partners and patients via WeedMD’s website here. Read more about the oil sales license here. WeedMD will continue to focus on securing further supply contracts in the seniors’ care market, offering its proprietary integrated care program along with its cannabis products. The Company’s expansion into a large-scale modern greenhouse will be the main supply source for its medical cannabis patients as well as for the future adult-use market.  For more about the expansion, read here.

For more information, access our investor presentation here and corporate video here.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. The Company is focused on providing medical cannabis to the long-term care, assisted living and seniors’ markets in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

Follow WeedMD On:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company-beta/5020743/
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.
Keith Merker, Chief Financial Officer
Tel: 519-765-2440 Ext. 222
Email: investor@weedmd.com
To learn more, visit us at www.weedmd.com
For Media Inquiries:
Marianella delaBarrera
Margin Communications & Public Relations
Tel: 416-897-6644
Email: marianella@marginpr.com

Forward-Looking Information

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Click here to connect with WeedMD Inc.(TSXV:WMD) for an Investor Presentation. 

Source: globenewswire.com

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less